Skip to main content

Table 2 Change in cell marker expression following treatment in the responder and non-responder groups

From: Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study

    Week 0 Week 12 P-value
CD3 etanercept R n = 12 27.5 (6.5 to 1121) 16 (0.5 to 113) 0.05*
   NR n = 1 17 14 n/a
  anakinra R n = 4 33.5 (1 to 1344) 32.9 (3 to 734) 0.47
   NR n = 4 87.9 (13 to 265) 300 (166 to 389) 0.068
CD68sl etanercept R n = 12 127 (138 to 3,543) 712 (112 to 2,318) 0.31
   NR n = 1 1,408 1,667 n/a
  anakinra R n = 4 1,370 (362 to 2,685) 1,444 (453 to 2,414) 0.72
   NR n = 4 1,431 (494 to 1,795) 1,879 (1,741 to 2,218) 0.068
CD68ll etanercept R n = 12 226 (38 to 513) 213 (17 to 466) 0.48
   NR n = 1 191 150 n/a
  anakinra R n = 4 174 (129 to 469) 214 (154 to 473) 0.47
   NR n = 4 159 (108 to 197) 147 (104 to 319) 0.72
FVlll etanercept R n = 11 132,242 (43,272 to 754,550) 139,294 (51,817 to 439,712) 0.53
   NR n = 1 58,525 142,834 n/a
  anakinra R n = 4 218,619 (88,372 to 353,725) 280,785 (226,415 to 353,725) 0.27
   NR n = 4 286,939 (84,419 to 521,103) 437,447 (184,155 to 545,675) 0.72
MRI etanercept R n = 13 8 (4 to 12) 5 (2 to 11) 0.12
   NR n = 1 3 1 n/a
  anakinra R n = 5 4 (4 to 12) 4 (4 to 9) 0.66
   NR n = 3 4 (0 to 11) 4 (4 to 7) 1
  1. Median (range). n/a, not applicable; NR, non-responder; R, responder